Sanofi Teams Up With RadioMedix, Orano Med to Develop Rare Cancer Treatment

By Andrea Figueras

Sanofi said it entered into an exclusive licensing agreement with U.S. clinical-stage biotechnology company RadioMedix and Orano Med, a French subsidiary of the Orano Group, to develop innovative treatments for rare cancers.

The collaboration is focused primarily on the AlphaMedix late-stage project, which is being evaluated for the treatment of adult patients with a rare cancer, Sanofi said Thursday.

RadioMedix develops radiopharmaceuticals for PET imaging and therapy, while Orano Med is focused on targeted therapies against cancer using an alpha-emitting radioisotope and Targeted Alpha-Emitter Therapy, one of the more potent therapeutic payloads against cancer cells.

Following the deal, Sanofi will be responsible for the commercialization of AlphaMedix, while Orano Med will manufacture it through its global industrial platform, currently under development.

RadioMedix and Orano Med will receive an upfront payment of 100 million euros ($110.1 million) and up to 220 million euros in sales milestones and be eligible for tiered royalties.

Write to Andrea Figueras at andrea.figueras@wsj.com

(END) Dow Jones Newswires

September 12, 2024 01:46 ET (05:46 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.